共同靶向PI3K-Akt通路可改善低级别浆液性卵巢癌细胞系对MEK抑制的应答
本研究在低级别浆液性卵巢癌(LGSOC)细胞系中进行激酶组CRISPR敲除筛选,发现PI3K-Akt通路激酶缺失与曲美替尼耐药细胞群扩增相关;MEK抑制后Akt信号上调,联合AKT抑制剂capivasertib在体外产生协同抗增殖效应。
要点
- LGSOC细胞系激酶组CRISPR筛选发现PI3K-Akt通路激酶与曲美替尼存在合成致死相互作用。
- MEK抑制后LGSOC细胞系中Akt信号上调,单独抑制AKT影响很小。
- 曲美替尼联合capivasertib在体外对LGSOC细胞增殖产生强协同抑制。
核心结论
- LGSOC通过上调PI3K-Akt信号对MEK抑制产生应答,从而促进细胞存活和增殖。
- 单独靶向抑制AKT影响很小,但与MEK抑制剂联合在LGSOC细胞中产生强协同增殖抑制。
- 该联合策略可能用于预防或逆转LGSOC患者中MEK抑制剂耐药的出现。
研究设计与样本
- 在LGSOC细胞系中进行激酶组CRISPR敲除筛选,以识别曲美替尼处理与特定蛋白激酶缺失之间的合成致死相互作用。
- 候选基因通过蛋白质印迹和细胞活力实验进行评估。
主要发现
- CRISPR激酶组筛选识别出若干蛋白激酶,尤其是PI3K-Akt通路中的激酶,其缺失与曲美替尼耐药LGSOC细胞群扩增相关,提示合成致死相互作用。
- 蛋白质印迹证实在一组LGSOC细胞系中MEK抑制后Akt信号上调。
- 通过capivasertib共抑制AKT阻止该上调,在体外产生协同抗增殖效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Low-grade serous ovarian cancer (LGSOC) frequently harbors genetic alterations that activate the MAPK pathway, providing an oncogenic target for therapeutic intervention. Recent clinical trials utilizing inhibitors of MEK (a key mediator of MAPK signaling), particularly trametinib or avutometinib/defactinib combination, have shown efficacy in patients with recurrent LGSOC. Unfortunately, however, nearly all patients eventually develop therapeutic resistance and progressive disease, which confers a dismal prognosis. Here, we aim to characterize biological responses of LGSOC to MEK inhibition at the molecular level. METHODS: We performed a kinome-focused CRISPR knockout screen in LGSOC cell lines to identify synthetic lethal interactions between trametinib treatment and loss of specific protein kinases. Candidates were evaluated using western blotting and cell viability assays. RESULTS: CRISPR kinome screens identified several protein kinases, particularly within the PI3K-Akt pathway, whose loss correlated with outgrowth of trametinib-resistant LGSOC cell populations, indicative of synthetic lethal interaction. Western blotting confirmed upregulation of Akt signaling upon MEK inhibition in a panel of LGSOC cell lines, and preventing this upregulation by co-inhibiting AKT with capivasertib produced synergistic antiproliferative effects in vitro. CONCLUSION: LGSOC responds to MEK inhibition by upregulating PI3K-Akt signaling, thereby promoting cell survival and proliferation. Our research identified significant upregulation of the PI3K-Akt pathway in response to MEK inhibition. While targeted inhibition of AKT had minimal impact alone, combination with MEK inhibitors produced strong synergistic suppression of proliferation in LGSOC cells. This combination strategy could potentially be used to prevent or reverse the emergence of MEK inhibitor resistance in LGSOC patients.
引用
- Peplinski RM, Riordan JD, Schillo JL, et al. Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines. Gynecol Oncol. 2025. PMID: 41351945. doi:10.1016/j.ygyno.2025.11.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。